In cancer, TIA1 dysregulation has been reported in leukemia and lung cancer [30,31,32], yet its metabolic or immunological functions remain largely unexplored, and no study has connected TIA1 to BCG responsiveness in urothelial malignancy. This evidence concerns the gene TIA1 and lung carcinoma.